NATCO PHARMA LTD.

Natco Pharma Limited, through its U.S. subsidiary NATCO Pharma USA LLC, has announced the launch of Carboplatin Injection, a generic version of Paraplatin®, in the U.S. market. This launch, in collaboration with Teyro Labs Pvt Ltd, aims to address a critical shortage of the product. Carboplatin Injection is used for the treatment of advanced ovarian carcinoma. The U.S. market for Carboplatin Injection had estimated sales of USD 27.8 million for the 12 months ending June 2026, according to industry sales data.

Natco Pharma Ltd announced that its promoter, V. C. Nannapaneni, has created a pledge of 8,50,000 equity shares of Rs. 2/- each. This disclosure was made on October 12, 2026, under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, and also under Regulation 7(2) read with Regulation 6(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015. The filing details the holding before and after the pledge, indicating the transaction type as 'Pledge'. The specific percentages of total capital held before and after the transaction are provided in the filing.

Natco Pharma Ltd has announced the closure of its trading window for dealing in the company's securities. This restriction applies to Directors, Designated Persons, their immediate relatives, and other connected persons as per SEBI (Prohibition of Insider Trading) Regulations, 2015. The window will be closed effective October 1, 2026, and will reopen 48 hours after the declaration of the Unaudited Financial Results for the quarter ending September 30, 2026. The exact date of the board meeting to approve these results will be communicated later.

Natco Pharma Limited's Fund Raising Committee has approved the Letter of Offer for its upcoming Rights Issue. The company has obtained ISIN: INE987B20018 for the Rights Entitlements. The issue involves up to 17,058,082 fully paid-up equity shares of face value ₹2 each, at a price of ₹750 per share, aggregating up to ₹12,794 million. This is offered on a rights basis to eligible equity shareholders in the ratio of 2 rights equity shares for every 21 fully paid-up equity shares held as of the Record Date, October 1, 2026. The Letter of Offer is being submitted to SEBI in compliance with relevant regulations.

NATCO Pharma Limited has decided to increase its investment in eGenesis, Inc. from the previously disclosed US$14.00 million to US$16.70 million through its wholly-owned subsidiaries. This updated investment, combined with an earlier US$8.00 million investment in 2024, brings NATCO's total investment in eGenesis to US$24.70 million. The investment is being made by NATCO Pharma (Canada) Inc. (US$13.70 million) and NATCO Pharma USA LLC (US$3 million) via convertible promissory notes. eGenesis, Inc. is a biotechnology company pioneering genome engineering for developing transplantable organs to address the global organ shortage, having recently achieved the world's first porcine kidney transplant in a living patient.

Natco Pharma Ltd has announced that its Board of Directors has fixed Thursday, October 1, 2026, as the record date for its upcoming Rights Issue. This date will be used to determine which shareholders are eligible to receive the Rights Entitlements for the equity shares being offered.

Natco Pharma Limited's Board of Directors, in a meeting held on September 25, 2026, approved a rights issue of equity shares amounting to ₹1,279.36 crore. The issue will offer 17,058,082 equity shares at a price of ₹750 per share, including a premium of ₹748. The rights entitlement ratio is 2 equity shares for every 21 held as of the record date, October 1, 2026. The rights issue will open on October 12, 2026, and close on October 22, 2026. The company's outstanding equity shares will increase from 179,109,870 to 196,167,952 assuming full subscription.

Natco Pharma Limited's Board of Directors has approved a Rights Issue to raise up to ₹1,279.36 crore by issuing equity shares at ₹750 each. The issue will offer 2 equity shares for every 21 held, with a record date set for October 1, 2026. The Rights Issue will open on October 12, 2026, and close on October 22, 2026. This move aims to strengthen the company's capital base.

Natco Pharma Ltd has announced that its Board of Directors will convene on September 25, 2026. The primary agenda for this meeting is to consider, discuss, and finalize various aspects related to the previously approved rights issue, which aims to raise an amount not exceeding ₹1,300 crores. Key terms to be determined include the rights issue price, payment mechanism, rights entitlement ratio, record date, and the overall timing of the rights issue. In compliance with SEBI regulations, the trading window for designated persons and their relatives will be closed from September 23, 2026, until 48 hours after the board meeting outcome is intimated to the stock exchanges.

Natco Pharma Ltd has received in-principle approval from both the National Stock Exchange of India Limited and BSE Limited for its upcoming Rights Issue of fully paid-up equity shares. The approval was granted on September 21, 2026. Further details and the approval letters are available on the company's investor relations website.